• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300003.SZ
Share

Lepu Medical Technology Stocks

CN¥ 12.15Last Updated 26.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 3.33B

CN¥ 12.15
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1999 and headquartered in Beijing, China, Lepu Medical Technology is a prominent company dedicated to the research, development, production, and sale of a broad spectrum of medical devices, pharmaceuticals, and healthcare services. The company's extensive medical device portfolio primarily focuses on cardiovascular health. This includes interventional cardiology products such as coronary stents, balloons, catheters, guide wires, and related PCI accessories. It also provides solutions for structural heart diseases, like occluders, vascular plugs, delivery systems, and mechanical heart valves. Lepu Medical offers cardiac rhythm management products, including pacemakers, equipment, leads, and electrophysiology systems, alongside products for off-pump coronary artery bypass grafting and peripheral interventional devices such as PTA balloons and guide wires. Beyond cardiovascular applications, their offerings extend to critical care products like vascular access devices, needle-free connectors, blood samplers, and pressure transducers. The company also provides digital subtraction angiography (DSA) systems (both floor and suspended types), in vitro diagnostic (IVD) equipment and biomarkers, hemodialysis catheters and hollow fiber dialyzers, and general surgery instruments including surgical staplers and endo surgery accessories. In the pharmaceutical sector, Lepu Medical manufactures and distributes medications for various conditions. This encompasses a comprehensive range of cardiovascular drugs designed to treat issues like thrombosis, hyperlipidemia, hypertension, angina, and heart failure. Additionally, they produce beta-lactamase antibiotics and antifungal antimicrobial drugs, central nervous system medications (such as painkillers and antidepressants), treatments for gastric/duodenal ulcers and chronic liver disease, respiratory system drugs, hypoproteinemia drugs, and agents that activate blood circulation. Furthermore, Lepu Medical provides a diverse array of healthcare services. These include precision medicine, remote ECG telemonitoring, and specialized consulting and management centers for cardiovascular diseases. The company is also involved in medical science and technology incubation, equity investment, and offers medical financial services. Its service offerings extend to general health consultation, online pharmacy platforms, sales of household medical equipment, smart medical devices, and the operation of specialized hospitals focusing on cardiovascular care. Lepu Medical actively participates in the establishment and co-construction of cardiac catheterization laboratories (Cath Labs).

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300003.SZ is 18.9 and suggests 53.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 01:51

Anthropic Disclosed Its Reliance on Google, Amazon, and Microsoft Ahead of Its IPO. What Is the Risk?

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026